Hepcidin agonists are classified into hepcidin mimetics (e.g., Rusfertide), stimulators of hepcidin production (e.g., Sapablursen and SLN124), and ferroprotein inhibitors (e.g., Vamifeprot), which are used to treat various iron dysregulation disorders, including polycythemia vera, thalassemia, hemochromatosis, and anemia of chronic disease [30, 31]. Here, HAMP is linked to anemia (phenotype).